|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||71.08 - 71.98|
|52 Week Range||51.12 - 74.42|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||46.25|
|Forward Dividend & Yield||0.33 (0.45%)|
|Ex-Dividend Date||Jul 10, 2020|
|1y Target Est||80.78|
HYDERABAD, India and Princeton, N.J., Jun 22, 2021--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration (USFDA).
Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several countries to treat patients with mild to moderate cases of COVID-19.
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.